Literature DB >> 8013261

Occurrence of IDDM during interferon therapy for chronic viral hepatitis.

M Waguri1, T Hanafusa, N Itoh, A Imagawa, J Miyagawa, S Kawata, N Kono, M Kuwajima, Y Matsuzawa.   

Abstract

We report a case of IDDM which occurred during interferon therapy for chronic hepatitis. A 31-year-old man intermittently received 2.5 x 10(8) units of alpha-IFN and 1 x 10(8) units of beta-IFN for treatment of chronic viral hepatitis type B. Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started. After the start of insulin therapy, there was a remission period for about 3 years but insulin-dependency recurred thereafter. The clinical course of this case indicates that IFN therapy precedes IDDM. During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8013261     DOI: 10.1016/0168-8227(94)90124-4

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  12 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy.

Authors:  Ferdinando C Sasso; Ornella Carbonara; Pierpaolo Di Micco; Leonardo Coppola; Roberto Torella; Alferio Niglio
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

Review 3.  Diabetes mellitus during interferon therapy for chronic viral hepatitis.

Authors:  Ali Mofredj; Mehran Howaizi; Denis Grasset; Henri Licht; Sylvie Loison; Bruno Devergie; Renato Demontis; Jean-François Cadranel
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

4.  Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B.

Authors:  J Cianciara; T Laskus
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

5.  Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis.

Authors:  A Imagawa; N Itoh; T Hanafusa; M Waguri; M Kuwajima; Y Matsuzawa
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

Review 6.  The role of interleukin-1 in the pathogenesis of IDDM.

Authors:  T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

Review 7.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

8.  Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis.

Authors:  E di Cesare; M Previti; F Russo; S Brancatelli; M C Ingemi; R Scoglio; N Mazzù; D Cucinotta; G Raimondo
Journal:  Dig Dis Sci       Date:  1996-08       Impact factor: 3.199

Review 9.  Cytokine-induced autoimmune disorders.

Authors:  P Miossec
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

Review 10.  [Interferon therapy and autoimmunity].

Authors:  J Fritzsch; J Krug; H J Heberling
Journal:  Med Klin (Munich)       Date:  1997-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.